Maryland AG Files Suit Against Drug Companies for Blocking Competitors’ Production of Generic Cholesterol Lowering Drug
BALTIMORE, MD (March 18, 2008) - Maryland Attorney General Douglas F. Gansler today filed suit against Abbott Laboratories and French drug company Fournier Industrie et Sante alleging that the firms violated state and federal antitrust laws by delaying the availability of cheaper, generic versions of TriCor, a cholesterol drug which last year accounted for over one billion dollars of Abbott’s sales.
The civil complaint filed in federal court in Delaware alleges that the two drug companies conspired to prevent the marketing of less expensive generic versions of TriCor, Abbott’s brand name for fenofibrate, a drug used to reduce high levels of triglycerides and cholesterol.
The complaint alleges that Abbott and Fournier obtained patents protecting TriCor from competition by deceiving the Patent Office with incomplete and misleading data. Abbott and Fournier then brought more than 10 groundless patent infringement lawsuits against these generic companies between 2000 and 2004 to prevent them from obtaining Federal Food and Drug Administration approval to market their generic versions of Tricor. Abbott and Fournier eventually lost or dismissed all of the lawsuits.
Abbott and Fournier also made minor changes in the formulations of TriCor, not to improve it, but to prevent competing drug companies’ generic versions from qualifying under FDA rules as substitutes for the more costly TriCor. Abbott and Fournier further ensured that TriCor would not face generic competition by withdrawing earlier TriCor versions from the market before generic substitutes to these versions could be marketed. When consumers purchase generic versions of major brand name drugs, the price is often 50-80 percent less than the branded drug.
“Many Marylanders struggle to pay for the drugs that they need to preserve their health,” said Attorney General Gansler. “We cannot tolerate schemes that artificially increase the burdens on our citizens and on the State.”
Maryland’s lawsuit seeks three times the amount of overpayments made by the State and by Marylanders who purchased TriCor. Maryland was joined in this suit by Arizona, Arkansas, California, Connecticut, the District of Columbia, Florida, Iowa, Kansas, Maine, Minnesota, Missouri, Nevada, New York, Oregon, Pennsylvania, South Carolina, Washington, and West Virginia.
Source: Maryland Attorney General
Scroll down for related articles:
Related articles
- 2008-03-19: Maryland AG Files Suit Against Drug Companies for Blocking Competitors’ Production of Generic Cholesterol Lowering Drug
- 2008-03-19: Missouri AG Nixon Sues Pharmaceutical Companies Abbott And Fournier For Illegally Blocking Generic Competition To TriCor
- 2008-03-19: Florida, 18 States Sue Abbott Laboratories for Blocking Generic Prescription Competition
- 2009-03-12: AARP: Biologics Bill Will Lower Prices of Most Expensive Drugs
- 2009-03-11: New Website Will Help PA Consumers Find Lowest Local Prices for Prescription Drugs
- 2008-05-22: Illinois AG Madigan, 29 States Reach $58 Million Settlement With Merck
- 2008-05-22: Idaho to Receive More than $1.1 Million from Vioxx Maker Merck
- 2008-05-22: Florida AG Files $58 Million Multistate Judgment to Resolve Three-Year Investigation into Merck Pharmaceutical
- 2008-05-22: $58 Million Merck Settlement To Change Deceptive TV Drug Advertisements
- 2008-04-28: AGs Join to Provide Prescription Drug Information
- 2008-03-19: California AG Brown Sues Abbott And Fournier for Blocking Generic Cholesterol Drug
- 2009-10-20: FDA approves GlaxoSmithKline’s Votrient for advanced renal cell cancer